Hundreds of patients with breast cancer and advanced prostate cancer could benefit from a breakthrough targeted therapy, after the NHS agreed a landmark commercial deal to roll-out the drug to treat forms of the two most common cancers in England. The drug, olaparib (Lynparza®), targets cancers with mutations in the BRCA genes, and works by […]
Read More on the NHS website.